Focus on Lymphoma
“Imbruvica’s approval demonstrates the FDA’s commitment to making treatments available to patients with rare diseases."
The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer. Imbruvica is intended for patients with MCL who have received at least one prior therapy. It works by inhibiting the enzyme needed by the cancer to multiply and spread. Imbruvica is the third drug approved to treat MCL. Velcade (2006) and Revlimid (2013) are also approved to treat the disease.
by Katherine L. Byar, MSN, APN, BC, and Julie M. Vose, MD
Improvements in therapy have increased survival rates for many people with non-Hodgkin lymphoma. However, NHL survivors are still at risk for developing late complications after treatment ends. Routine follow-ups are needed to assess any long-term side effects of therapy and to check for signs of cancer recurrence.
by Susan Thornton
The Cutaneous Lymphoma Foundation, a nonprofit patient advocacy organization, strives to support each person with cutaneous lymphoma by promoting awareness and education, advancing patient care, and facilitating research. Cutaneous lymphoma is a rare form of non-Hodgkin lymphoma that develops in the skin.